Corvus Pharmaceuticals CBO Arcara acquires $50,475 in company stock

Corvus Pharmaceuticals CEO Jeffrey Arcara recently purchased 4,500 shares of company stock, totaling $50,475, over multiple transactions in November 2026. The shares were bought between November 11 and November 13, 2026, at prices ranging from $10.37 to $11.4602 per share. The current trading price of the stock is $10.64, and according to InvestingPro analysis, the stock appears undervalued with a Fair Value of $11.14, indicating potential upside from its current levels.

Despite the recent acquisitions, Corvus Pharmaceuticals reported a wider third-quarter loss than expected, with adjusted earnings per share at -$0.22, falling short of the consensus estimate of -$0.19. The company has been increasing its research and development spending, with expenditures more than doubling from the previous year to support clinical activity for its lead asset, soquelitinib.

Mizuho Securities reiterated an Outperform rating for Corvus Pharmaceuticals, maintaining a price target of $27.00, following the company's third-quarter results. The firm highlighted updated timelines for soquelitinib, which is being developed for oncology and autoimmune conditions. The recent financial performance, however, has led investors to weigh the wider loss against the company's ongoing research efforts and future potential.